India’s fair trade watchdog, the Competition Commission of India, has dismissed five complaints against the Jaypee Group companies for alleged abuse of their dominant position in the real estate market of Noida and Greater Noida.
The Commission, in a majority verdict, said in its “considered opinion JAL/ JIL does not enjoy a position of dominance in the market for provision of services for the development and sale of residential apartments in Noida and Greater Noida in accordance with the provisions of section 4 of the Act.”
“Since JAL/ JIL is not in a dominant position in the relevant market, the question of examining the alleged abusive conduct does not arise,” the order added.
Two CCI members ordered a Rs.666 crore fine on Jaypee associates, but were overruled by the chairman and other members.
The commission, however, also asked the company and other players in the real estate sector to take appropriate voluntary measures to address the concerns of the flat buyers.
The informants in the cases had alleged that Jaiprakash Associates, along with its group company Jaypee Infratech, abused its dominant position by imposing highly arbitrary, unfair and unreasonable conditions in the agreements for allotment of residential apartments which blatantly violated the principles of free and fair competition.
The two dissenting members disagreed with the majority verdict and found the Jaypee Group “clearly dominant in the relevant market”.
Full content: The Economic Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas